| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
|
N Engl J Med
|
2012
|
52.99
|
|
2
|
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
|
N Engl J Med
|
2012
|
35.24
|
|
3
|
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
|
J Clin Oncol
|
2010
|
17.13
|
|
4
|
Inflammation in prostate carcinogenesis.
|
Nat Rev Cancer
|
2007
|
9.08
|
|
5
|
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
|
Curr Opin Immunol
|
2012
|
7.26
|
|
6
|
Role of LAG-3 in regulatory T cells.
|
Immunity
|
2004
|
4.36
|
|
7
|
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity.
|
J Immunol
|
2007
|
4.29
|
|
8
|
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
|
Cancer Res
|
2011
|
3.81
|
|
9
|
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.
|
Clin Cancer Res
|
2012
|
3.68
|
|
10
|
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing.
|
Clin Cancer Res
|
2008
|
3.09
|
|
11
|
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
|
Blood
|
2007
|
2.93
|
|
12
|
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.
|
Cancer Res
|
2013
|
2.81
|
|
13
|
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells.
|
Science
|
2009
|
2.76
|
|
14
|
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.
|
Blood
|
2007
|
2.69
|
|
15
|
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.
|
Blood
|
2005
|
2.60
|
|
16
|
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.
|
J Clin Invest
|
2007
|
2.57
|
|
17
|
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.
|
Lancet Oncol
|
2012
|
2.31
|
|
18
|
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
|
Int J Radiat Oncol Biol Phys
|
2013
|
2.28
|
|
19
|
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.
|
Prostate
|
2009
|
2.17
|
|
20
|
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
|
Clin Cancer Res
|
2011
|
1.97
|
|
21
|
B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells.
|
J Immunol
|
2005
|
1.78
|
|
22
|
A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells.
|
Mol Immunol
|
2010
|
1.65
|
|
23
|
Bacteriolytic therapy can generate a potent immune response against experimental tumors.
|
Proc Natl Acad Sci U S A
|
2004
|
1.63
|
|
24
|
The composition and signaling of the IL-35 receptor are unconventional.
|
Nat Immunol
|
2012
|
1.63
|
|
25
|
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.
|
Cancer Epidemiol Biomarkers Prev
|
2014
|
1.61
|
|
26
|
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.
|
Proc Natl Acad Sci U S A
|
2006
|
1.61
|
|
27
|
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.
|
J Immunol
|
2009
|
1.60
|
|
28
|
LAG-3 in Cancer Immunotherapy.
|
Curr Top Microbiol Immunol
|
2011
|
1.58
|
|
29
|
Tc17 CD8 T cells: functional plasticity and subset diversity.
|
J Immunol
|
2009
|
1.54
|
|
30
|
Phenotypic and functional properties of Helios+ regulatory T cells.
|
PLoS One
|
2012
|
1.52
|
|
31
|
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.
|
Cancer Res
|
2009
|
1.51
|
|
32
|
Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II.
|
Prostate
|
2009
|
1.45
|
|
33
|
A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression.
|
J Pathol
|
2015
|
1.45
|
|
34
|
Parabolic resection for mitral valve repair.
|
Interact Cardiovasc Thorac Surg
|
2009
|
1.39
|
|
35
|
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
|
Clin Cancer Res
|
2013
|
1.39
|
|
36
|
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.
|
Clin Cancer Res
|
2011
|
1.38
|
|
37
|
LAG-3 regulates plasmacytoid dendritic cell homeostasis.
|
J Immunol
|
2009
|
1.33
|
|
38
|
Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3.
|
J Immunol
|
2011
|
1.28
|
|
39
|
Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.
|
J Immunol
|
2004
|
1.21
|
|
40
|
CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction.
|
J Immunol
|
2003
|
1.19
|
|
41
|
Radiotherapy augments the immune response to prostate cancer in a time-dependent manner.
|
Prostate
|
2008
|
1.17
|
|
42
|
Prostate cancer immunotherapy.
|
Clin Cancer Res
|
2011
|
1.11
|
|
43
|
Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4.
|
Eur J Immunol
|
2010
|
1.09
|
|
44
|
Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.
|
J Immunol
|
2009
|
1.07
|
|
45
|
Current status of immunological therapies for prostate cancer.
|
Curr Opin Urol
|
2010
|
1.06
|
|
46
|
STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model.
|
J Immunol
|
2009
|
1.06
|
|
47
|
Allogeneic versus autologous blood transfusion and survival after radical prostatectomy.
|
Transfusion
|
2014
|
1.00
|
|
48
|
Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies.
|
Cancer Causes Control
|
2010
|
0.99
|
|
49
|
Cutting Edge: TCR-induced NAB2 enhances T cell function by coactivating IL-2 transcription.
|
J Immunol
|
2006
|
0.98
|
|
50
|
Immunotherapy for prostate cancer: walk, don't run.
|
J Clin Oncol
|
2009
|
0.96
|
|
51
|
Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.94
|
|
52
|
Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data.
|
PLoS Med
|
2009
|
0.94
|
|
53
|
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.
|
J Transl Med
|
2013
|
0.93
|
|
54
|
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
|
Curr Opin Oncol
|
2012
|
0.92
|
|
55
|
Immunotherapy for prostate cancer: recent developments and future challenges.
|
Cancer Metastasis Rev
|
2014
|
0.90
|
|
56
|
Immune modulation and stereotactic radiation: improving local and abscopal responses.
|
Biomed Res Int
|
2013
|
0.90
|
|
57
|
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.
|
Urology
|
2013
|
0.89
|
|
58
|
Immune signatures predict prognosis in localized cancer.
|
Cancer Invest
|
2010
|
0.88
|
|
59
|
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.
|
Oncology (Williston Park)
|
2015
|
0.85
|
|
60
|
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
|
J Natl Cancer Inst
|
2012
|
0.83
|
|
61
|
Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium.
|
J Urol
|
2006
|
0.82
|
|
62
|
Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation.
|
J Pharmacol Exp Ther
|
2009
|
0.82
|
|
63
|
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
|
Prostate
|
2011
|
0.81
|
|
64
|
Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.81
|
|
65
|
Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.
|
Prostate
|
2011
|
0.81
|
|
66
|
Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells.
|
Immunol Cell Biol
|
2011
|
0.80
|
|
67
|
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more.
|
Oncoimmunology
|
2012
|
0.78
|
|
68
|
Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'?
|
Oncology (Williston Park)
|
2014
|
0.78
|
|
69
|
Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy.
|
Cancer Res
|
2007
|
0.77
|
|
70
|
Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice.
|
Prostate
|
2012
|
0.77
|
|
71
|
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.
|
BioDrugs
|
2014
|
0.76
|
|
72
|
Personalized Immune Therapy: A Slippery Fish?
|
Oncology (Williston Park)
|
2016
|
0.75
|
|
73
|
Current immunotherapeutic strategies in prostate cancer.
|
Surg Oncol Clin N Am
|
2007
|
0.75
|
|
74
|
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.
|
Am J Surg Pathol
|
2017
|
0.75
|
|
75
|
Combination immunotherapy in renal cell carcinoma.
|
Clin Adv Hematol Oncol
|
2016
|
0.75
|